230.83
price down icon0.14%   -0.32
after-market Dopo l'orario di chiusura: 230.75 -0.08 -0.03%
loading
Precedente Chiudi:
$231.15
Aprire:
$233.6
Volume 24 ore:
891.71K
Relative Volume:
1.41
Capitalizzazione di mercato:
$15.14B
Reddito:
$1.01B
Utile/perdita netta:
$581.90M
Rapporto P/E:
26.01
EPS:
8.8733
Flusso di cassa netto:
$50.57M
1 W Prestazione:
+7.06%
1M Prestazione:
-2.87%
6M Prestazione:
+15.53%
1 anno Prestazione:
+35.22%
Intervallo 1D:
Value
$230.23
$237.00
Intervallo di 1 settimana:
Value
$216.50
$237.00
Portata 52W:
Value
$160.86
$250.74

Ascendis Pharma A S Stock (ASND) Company Profile

Name
Nome
Ascendis Pharma A S
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
1,189
Name
Cinguettio
Name
Prossima data di guadagno
2026-08-06
Name
Ultimi documenti SEC
Name
ASND's Discussions on Twitter

Compare ASND vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ASND icon
ASND
Ascendis Pharma A S
230.83 15.14B 1.01B 581.90M 50.57M 8.8733
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
451.63 114.63B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
609.94 63.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
877.72 54.58B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.09 37.13B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
162.99 34.65B 742.00K -1.37B -1.07B -7.0731

Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-03-16 Ripresa Jefferies Buy
2026-01-28 Iniziato Barclays Overweight
2025-11-18 Iniziato Wolfe Research Peer Perform
2025-10-17 Iniziato Raymond James Strong Buy
2025-07-03 Ripresa Morgan Stanley Overweight
2025-05-05 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2025-04-16 Iniziato RBC Capital Mkts Outperform
2025-01-07 Iniziato UBS Buy
2024-09-05 Aggiornamento Oppenheimer Perform → Outperform
2024-06-25 Aggiornamento TD Cowen Hold → Buy
2024-05-31 Iniziato Stifel Buy
2023-12-20 Iniziato Jefferies Buy
2023-06-14 Ripresa Credit Suisse Neutral
2023-04-05 Downgrade Oppenheimer Outperform → Perform
2023-04-04 Downgrade Morgan Stanley Overweight → Equal-Weight
2023-04-03 Downgrade Credit Suisse Outperform → Neutral
2022-10-20 Iniziato Goldman Buy
2022-08-30 Ripresa Berenberg Buy
2022-03-28 Ripresa Wedbush Outperform
2022-03-15 Aggiornamento BofA Securities Neutral → Buy
2022-03-01 Iniziato Citigroup Buy
2022-02-14 Aggiornamento Oppenheimer Perform → Outperform
2022-01-06 Iniziato Cowen Market Perform
2021-12-08 Iniziato Wells Fargo Overweight
2021-10-20 Downgrade BofA Securities Buy → Neutral
2021-03-30 Downgrade Oppenheimer Outperform → Perform
2021-03-11 Ripresa Stifel Buy
2020-12-17 Iniziato Berenberg Buy
2020-09-14 Ripresa JP Morgan Overweight
2020-03-20 Iniziato Oppenheimer Outperform
2019-10-11 Iniziato Morgan Stanley Overweight
2019-03-25 Iniziato Evercore ISI Outperform
2019-01-24 Iniziato Cantor Fitzgerald Overweight
2019-01-24 Aggiornamento Leerink Partners Mkt Perform → Outperform
2018-06-26 Iniziato Stifel Buy
2018-04-02 Reiterato Leerink Partners Mkt Perform
2017-05-11 Iniziato JP Morgan Overweight
2017-03-09 Downgrade Leerink Partners Outperform → Mkt Perform
2017-02-09 Iniziato Credit Suisse Outperform
2016-09-26 Iniziato Wedbush Outperform
Mostra tutto

Ascendis Pharma A S Borsa (ASND) Ultime notizie

pulisher
Jun 18, 2026

Ascendis Pharma A/S (ASND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Ascendis Pharma A/S (ASND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Ascendis Pharma A/S (ASND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Ascendis Pharma A/S (ASND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Ascendis Pharma A/S (ASND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Ascendis Pharma (NASDAQ: ASND) nets $187.5M from FDA PRV sale - Stock Titan

Jun 17, 2026
pulisher
Jun 16, 2026

BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $288 - Moomoo

Jun 16, 2026
pulisher
Jun 15, 2026

Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says - marketscreener.com

Jun 15, 2026
pulisher
Jun 15, 2026

Oppenheimer reiterates Ascendis Pharma stock rating on drug data - Investing.com UK

Jun 15, 2026
pulisher
Jun 15, 2026

Oppenheimer reiterates Ascendis Pharma stock rating on drug data By Investing.com - Investing.com Nigeria

Jun 15, 2026
pulisher
Jun 15, 2026

Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273 - Moomoo

Jun 15, 2026
pulisher
Jun 15, 2026

Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism - TipRanks

Jun 15, 2026
pulisher
Jun 15, 2026

Long-term TransCon PTH data from Ascendis Pharma (ASND) show sustained benefits - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Powerhouse with 36.97% Potential Upside - DirectorsTalk Interviews

Jun 15, 2026
pulisher
Jun 15, 2026

Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha

Jun 15, 2026
pulisher
Jun 14, 2026

Ascendis Pharma completes Phase 3 PaTHway Trial - TipRanks

Jun 14, 2026
pulisher
Jun 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 14, 2026
pulisher
Jun 13, 2026

(ASND) Risk Channels and Responsive Allocation - Stock Traders Daily

Jun 13, 2026
pulisher
Jun 13, 2026

Ascendis Pharma Reports Sustained Efficacy and Safety of TransCon PTH in Phase 3 PaTHway Trial for Hypoparathyroidism After Three and a Half Years - Quiver Quantitative

Jun 13, 2026
pulisher
Jun 13, 2026

Hormone shot helps hypoparathyroidism patients cut daily calcium and vitamin D - Stock Titan

Jun 13, 2026
pulisher
Jun 12, 2026

Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock. - Pluang

Jun 12, 2026
pulisher
Jun 12, 2026

Why Is Ascendis Pharma Stock Gaining Friday?Ascendis Pharma (NASDAQ:ASND) - Benzinga

Jun 12, 2026
pulisher
Jun 12, 2026

Ascendis boasts of long-term Yorvipath data for hypoparathyroidism - MSN

Jun 12, 2026
pulisher
Jun 12, 2026

Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism - TipRanks

Jun 12, 2026
pulisher
Jun 12, 2026

Five-year TransCon PTH trial results reported by Ascendis Pharma (ASND) - Stock Titan

Jun 12, 2026
pulisher
Jun 12, 2026

Ascendis reports 5-year data for hypoparathyroidism drug - Investing.com UK

Jun 12, 2026
pulisher
Jun 12, 2026

Ascendis reports 5-year data for hypoparathyroidism drug By Investing.com - Investing.com Australia

Jun 12, 2026
pulisher
Jun 11, 2026

Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years - Moomoo

Jun 11, 2026
pulisher
Jun 11, 2026

5-year trial: drug frees most hypoparathyroidism patients from supplements - Stock Titan

Jun 11, 2026
pulisher
Jun 11, 2026

Ascendis Pharma Named Among Top Profitable Growth Stocks: Market Recognition BuildsMid-Term Outlook - newsline.com

Jun 11, 2026
pulisher
Jun 10, 2026

Ascendis Pharma grants 27,030 employee warrants at $213.23 per share By Investing.com - Investing.com South Africa

Jun 10, 2026
pulisher
Jun 10, 2026

Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan - TipRanks

Jun 10, 2026
pulisher
Jun 10, 2026

Ascendis Pharma grants 27,030 employee warrants at $213.23 per share - Investing.com

Jun 10, 2026
pulisher
Jun 10, 2026

[6-K] Ascendis Pharma A/S Current Report (Foreign Issuer) | ASND SEC FilingForm 6-K - Stock Titan

Jun 10, 2026
pulisher
Jun 09, 2026

Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy - Yahoo Finance

Jun 09, 2026
pulisher
Jun 09, 2026

Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case By Investing.com - Investing.com Australia

Jun 09, 2026
pulisher
Jun 09, 2026

Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case - Investing.com

Jun 09, 2026
pulisher
Jun 08, 2026

10 Most Profitable Growth Stocks to Buy - Insider Monkey

Jun 08, 2026
pulisher
Jun 08, 2026

Ascendis Pharma A/S to Present Latest Data on Endocrinology Rare Disease Programs at ENDO 2026 - Quiver Quantitative

Jun 08, 2026
pulisher
Jun 08, 2026

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewswire Inc.

Jun 08, 2026
pulisher
Jun 08, 2026

Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness - simplywall.st

Jun 08, 2026
pulisher
Jun 08, 2026

Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness - Yahoo Finance

Jun 08, 2026
pulisher
Jun 08, 2026

Why Ascendis Pharma Stock Is Sinking Today - TipRanks

Jun 08, 2026
pulisher
Jun 08, 2026

Ascendis Pharma A/S (ASND) Stock Analysis: Unlocking a 40% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews

Jun 08, 2026
pulisher
Jun 08, 2026

Capital International Ltd. CA Sells 4,811 Shares of Ascendis Pharma A/S $ASND - MarketBeat

Jun 08, 2026
pulisher
Jun 06, 2026

Ascendis Pharma A/S Stock 12‑Month Price Target Raised to $295.6, Implies 40% Upside - TradingView

Jun 06, 2026
pulisher
Jun 06, 2026

TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND - MarketBeat

Jun 06, 2026
pulisher
Jun 05, 2026

The Option Play Of The Week (NASDAQ:ASND) - Seeking Alpha

Jun 05, 2026
pulisher
Jun 05, 2026

Westfield Capital Management Co. LP Cuts Stake in Ascendis Pharma A/S $ASND - MarketBeat

Jun 05, 2026
pulisher
Jun 05, 2026

ASND Technical Analysis | Trend, Signals & Chart Patterns | ASCENDIS PHARMA A/S (NASDAQ:ASND) - ChartMill

Jun 05, 2026
pulisher
Jun 04, 2026

Ascendis Pharma reports trial data on achondroplasia treatment - Investing.com

Jun 04, 2026

Ascendis Pharma A S Azioni (ASND) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$31.43
price up icon 0.74%
$90.89
price down icon 1.44%
$52.96
price down icon 1.38%
$63.96
price up icon 3.50%
ONC ONC
$270.15
price up icon 2.84%
$162.99
price up icon 3.31%
Capitalizzazione:     |  Volume (24 ore):